N-Acetyl Selank
Also known as Acetyl-Selank, N-Acetyl Selank amidate
N-Acetyl Selank is the N-terminally acetylated form of Selank — a peptide-chemistry stability modification. A research-use profile focused on the acetylation, not a rewrite of the parent.
This entry is deliberately narrow: it is about one chemical change. Take Selank — the tuftsin-derived heptapeptide profiled on its own page — and acetylate the N-terminus, and you get this derivative. The sequence underneath is unchanged; the modification sits at the front of the chain.
Why do it at all? The N-terminal alpha-amino group is a common point of first attack for aminopeptidases, the enzymes that trim peptides from their ends. Acetylation replaces that reactive free amine with a neutral acetyl cap, a routine medicinal-chemistry move for altering how quickly a short peptide is degraded and cleared. The point of this compound, in other words, is the terminus — not a new pharmacology.
For the sequence, the tuftsin lineage, and the research contexts, see the Selank monograph; this page covers what the acetyl group adds.
N-Acetyl Selank is Selank carrying an acetyl group (CH3CO-) on its N-terminal amine. Capping the free alpha-amino group removes a charged, enzymatically vulnerable terminus — a standard chemical modification used to blunt aminopeptidase attack and shift the molecule's stability profile.
What N-terminal acetylation does, chemically
Acetylation transfers an acetyl group onto the peptide's N-terminal amine, converting a positively charged, exposed amino terminus into a capped, neutral one. In protein biochemistry this is one of the most common of all terminal modifications, and it is used in synthetic peptide design to reduce susceptibility to exopeptidase cleavage from the N-side.
Because the change is confined to the terminus, the internal Thr-Lys-Pro-Arg tuftsin core and the Pro-Gly-Pro tail that define Selank are preserved. This is a modification of stability and handling character, not a redesign of the sequence.
Why the acetylated form is listed separately
Acetyl-Selank and Selank are catalogued as distinct research materials because their certificates, masses, and chromatographic behavior differ — the added acetyl group changes the molecular mass and can shift retention time. A certificate of analysis for this compound should reflect the acetylation, not read identically to plain Selank.
If you are cross-referencing the two, the mass difference attributable to the acetyl group is the tell. Confirm the batch identifier and that the reported structure specifies N-terminal acetylation.
These are research areas the compound is associated with in the literature — not medical claims or intended uses.
Handling & storage
Supplied lyophilized. Stored sealed and cold; reconstituted with bacteriostatic water only when a protocol requires it, then kept refrigerated. Handle per accepted laboratory practice.
Verify a certificate by lot →Common questions
It is the same heptapeptide sequence with an acetyl group capping the N-terminus. The modification is at the chain's front end; the tuftsin-derived core is unchanged.
The free N-terminal amine is a common site of enzymatic (aminopeptidase) cleavage. Acetylation caps it — a standard peptide-chemistry technique for altering degradation and stability characteristics.
Yes. The acetyl group changes the molecular mass and can shift HPLC retention, so the certificate should specify N-terminal acetylation rather than match plain Selank.
This monograph is a research-use reference. It describes composition and the contexts in which the compound has been studied — it is not medical advice, a description of effects, or a recommendation for use. Sold strictly for laboratory and research use; not for human or animal consumption.